Canaccord maintains $180 target on Natera stock post-NCCN update
Canaccord Genuity maintained a Buy rating on Natera (NASDAQ:NTRA) shares, with a price target of $180. Trading at $169.27, the $22.35 billion market cap company enjoys strong analyst support, with a ...
Natera comments on updated NCCN guidance for circulating tumor DNA
Natera (NTRA) commented on recent updates by the NCCN on circulating tumor DNA molecular residual disease testing in the Clinical Practice ...
NCCN Strengthens Guidance on ctDNA in Colon Cancer, Rectal Cancer, and Merkel Cell Carcinoma
Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and genetic testing, today commented on recent updates by the ...
The Manila Times9 小时
BioRay's ROR1-Targeting Dual-Epitope ADC Drug BR111 Receives Formal Clinical Trial Approval ...
On December 19, 2024, BioRay Pharmaceutical Co., Ltd. ('BioRay') announced that the National Medical Products Administration (NMPA) has accepted the clinical trial application for its self-developed ...
New Atlas22 小时
Existing cardiac drug helps keep cancer from spreading
One of cancer’s deadliest tricks is its ability to spread to other organs. An existing cardiac drug has now been found to reduce the risk of metastasis by dissolving circulating clusters of breast ...